NasdaqGM:PSNLLife Sciences
Can Personalis (PSNL) Turn NeXT Personal’s Multi‑Tumor MRD Data Into Durable Competitive Advantage?
In early June 2026, Personalis reported new clinical data from the ASCO Annual Meeting showing its NeXT Personal liquid biopsy test can detect minimal residual disease across six major solid tumors at ultra-low circulating tumor DNA levels, often well before imaging.
The breadth of evidence, ranging from colorectal and lung cancer to ovarian, endometrial, melanoma, and renal cell carcinoma, highlights NeXT Personal’s potential to inform earlier, less invasive treatment decisions across...